Bipiperidinyl derivatives of 23-hydroxybetulinic acid reverse resistance of HepG2/ADM and MCF-7/ADR cells

Anti-Cancer Drugs

Volumn 24, Issue 5, 2013, Pages 441-454

  Zhang, Dong Mei ^a   Li, Ying Jie ^a   Shu, Chang ^a   Ruan, Zhi Xiong ^a   Chen, Wei Min ^a   Yiu, Anita ^c   Peng, Ying Hui ^a   Wang, Jiao ^a   Lan, Ping ^a   Yao, Zhe ^a   Fung, Kwok Pui ^d   Fu, Li Wu ^b   Chen, Zhe Sheng ^e   Ye, Wen Cai ^a  

^a JINAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c Attardi Institute of Mitochondrial Biomedicine   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e ST JOHN'S UNIVERSITY   (United States)

Author keywords

23 hydroxybetulinic acid derivatives; ABCB1; HepG2 ADM; MCF 7 ADR; multidrug resistance

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3,23 O DIACETYL 17 1,4' BIPIPERIDINYL BETULINIC AMIDE; 3,23 O DIHYDROXY 17 1,4' BIPIPERIDINYL BETULINIC AMIDE; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; DOXORUBICIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; RHODAMINE 123; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VERAPAMIL; VINCRISTINE;

ARTICLE; CELL STRAIN HEPG2; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HEP G2 CELLS; HUMANS; MCF-7 CELLS; MOLECULAR DOCKING SIMULATION; P-GLYCOPROTEIN; PACLITAXEL; PIPERIDINES; RHODAMINE 123; TRITERPENES; VERAPAMIL; VINCRISTINE;

EID: 84875828430     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32835fcc77     Document Type: Article

References (41)

1. Baguley BC. Multidrug resistance in cancer. Methods Mol Biol 2010; 596:1-14.
2. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58. (Pubitemid 37328807)
3. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42:1007-1017. (Pubitemid 32645780)
4. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 2003; 10:159-165. (Pubitemid 36437822)
5. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455:152-162.
6. Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases, invited review article. FEBS J 2011; 278:3226-3245.
7. Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol 2010; 596:341-358.
8. Sun YL, Patel A, Kumar P, Chen ZS. Role of ABC transporters in cancer chemotherapy. Chin J Cancer 2012; 31:51-57.
9. Wang Z, Ravula R, Cao M, Chow M, Huang Y. Transporter-mediated multidrug resistance and its modulation by Chinese medicines and other herbal products. Curr Drug Discov Technol 2010; 7:54-66.
10. Molná r J, Engi H, Hohmann J, Molná r P, Deli J,Wesolowska O, et al. Reversal of multidrug resistance by natural substances from plants. Curr Top Med Chem 2010; 10:1757-1768.
11. Huang M, Jin J, Sun H, Liu GT. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol 2008; 62:1015-1026.
12. Zhou B, Xiao X, Xu L, Zhu L, Tan L, Tang H, et al. A dynamic study on reversal of multidrug resistance by ginsenoside Rh2 in adriamycin-resistant human breast cancer MCF-7 cells. Talanta 2012; 88:345-351.
13. Tang PM, Chan JY, Zhang DM, Au SW, Fong WP, Kong SK, et al. Pheophorbide a, an active component in Scutellaria barbata, reverses P-glycoprotein-mediated multidrug resistance on a human hepatoma cell line R-HepG2. Cancer Biol Ther 2007; 6:504-509. (Pubitemid 47328323)
14. Ye WC, Ji NN, Zhao SX, Liu JH, Ye T, McKervey M, et al. Triterpenoids from Pulsatilla chinensis. Phytochemistry 1996; 42:799-802. (Pubitemid 27096892)
15. Ji ZN, Ye WC, Liu GG, Hsiao W. 23-Hydroxybetulinic acid-mediated apoptosis is accompanied by decreases in bcl-2 expression and telomerase activity in HL-60 cells. Life Sci 2002; 72:1-9. (Pubitemid 35284550)
16. Liu WK, Ho JC, Cheung FW, Liu BP, Ye WC, Che CT. Apoptotic activity of betulinic acid derivatives on murine melanoma B16 cell line. Eur J Pharmacol 2004; 498:71-78. (Pubitemid 39208062)
17. Zheng Y, Zhou F,Wu X,Wen X, Li Y, Yan B, et al. 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel synergizes the antitumor activities of doxorubicin in vitro and in vivo. J Ethnopharmacol 2010; 128:615-622.
18. Zhou JP, Li D, Wu XM, Ye WC, Zhang LY. Synthesis and antitumor activity of derivatives of 23-hydroxybetulinic acid. Chin Chem Lett 2007; 18:1195-1198.
19. Lan P, Wang J, Zhang DM, Shu C, Cao HH, Sun PH, et al. Synthesis and antiproliferative evaluation of 23-hydroxybetulinic acid derivatives. Eur J Med Chem 2011; 46:2490-2502.
20. Bi Y, Xu J, Sun F,Wu X, Ye W, Sun Y, et al. Synthesis and biological activity of 23-hydroxybetulinic acid C-28 ester derivatives as antitumor agent candidates. Molecules 2012; 17:8832-8841.
21. Zhu P, Bi Y, Xu J, Li Z, Liu J, Zhang L, et al. Terpenoids. III: Synthesis and biological evaluation of 23-hydroxybetulinic acid derivatives as novel inhibitors of glycogen phosphorylase. Bioorg Med Chem Lett 2009; 19:6966-6969.
22. Zhang DM, Shu C, Chen JJ, Sodani K, Wang J, Bhatnagar J, et al. BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Mol Pharm 2012; 9:3147-3159.
23. Chan JY, Chu AC, Fung KP. Inhibition of P-glycoprotein expression and reversal of drug resistance of human hepatoma HepG2 cells by multidrug resistance gene (MDR1) antisense RNA. Life Sci 2000; 67:2117-2124.
24. Dai C, Tiwari AK, Wu CP, Su X, Wang SR, Liu D, et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008; 68:7905-7914.
25. Sauna ZE, Ambudkar SV. About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work. Mol Cancer Ther 2007; 6:13-23. (Pubitemid 46206664)
26. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 2009; 323:1718-1722.
27. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53:615-627. (Pubitemid 34177898)
28. Kartner N, Shales M, Riordan JR, Ling V. Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 1983; 43:4413-4419. (Pubitemid 13041881)
29. Singh SV, Nair S, Ahmad H, Awasthi YC, Krishan A. Glutathione S-transferases and glutathione peroxidases in doxorubicin-resistant murine leukemic P388 cells. Biochem Pharmacol 1989; 38:3505-3510. (Pubitemid 19250203)
30. Potmesil M, Hsiang YH, Liu LF, Bank B, Grossberg H, Kirschenbaum S, et al. Resistance of human leukemic and normal lymphocytes to druginduced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 1988; 48:3537-3543.
31. Rumsby MG, Drew L, Warr Jr. Protein kinases and multidrug resistance. Cytotechnology 1998; 27:203-224. (Pubitemid 29025470)
32. Lee SK, Shehzad A, Jung JC, Sonn JK, Lee JT, Park JW, et al. Protein kinase Ca protects against multidrug resistance in human colon cancer cells. Mol Cells 2012; 34:61-69.
33. Schondorf T, Hoopmann M, Breidenbach M, Rein DT, Gohring UJ, Becker M, et al. Dysregulation of protein kinase C activity in chemoresistant metastatic breast cancer cells. Anticancer Drugs 2004; 15:265-268. (Pubitemid 38429419)
34. Lin ST, Chou HC, Chang SJ, Chen YW, Lyu PC,Wang WC, et al. Proteomic analysis of proteins responsible for the development of doxorubicin resistance in human uterine cancer cells. J Proteomics 2012; 75:5822-5847.
35. Wang J, Song Y, Xu S, Zhang Q, Li Y, Tang D, et al. Down-regulation of ICBP90 contributes to doxorubicin resistance. Eur J Pharmacol 2011; 656:33-38.
36. Shi YQ, Qu XJ, Liao YX, Xie CF, Cheng YN, Li S, et al. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycinresistant K562/A02 cells. Eur J Pharmacol 2008; 584:66-71.
37. Ding PR, Tiwari AK, Ohnuma S, Lee JW, An X, Dai CL, et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/Pglycoprotein transporter. PLoS One 2011; 6:e19329.
38. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, et al. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol Pharmacol 2002; 61:974-981. (Pubitemid 34441761)
39. Wang RB, Kuo CL, Lien LL, Lien EJ. Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 2003; 28:203-228. (Pubitemid 36783098)
40. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem 2011; 50:161-178.
41. Pajeva IK, Wiese M. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J Med Chem 2002; 45:5671-5686. (Pubitemid 35453760)